for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

REFILE-Gilead Sciences wins reversal of $1.2 bln fine against Bristol Myers in patent case

(Refiles to add media packaging code)

Aug 26 (Reuters) - Gilead Sciences Inc escaped a $1.2 billion fine, after the Federal Circuit Court of Appeals on Thursday found the relevant parts of a Bristol Myers Squibb patent that Gilead’s Yescarta cancer drug allegedly infringed were invalid.

Last year, a federal judge increased the damages that Gilead would pay to Bristol Myers Squibb to $1.2 billion in a patent infringement case related to CAR T-cell immunotherapy for cancer. (Reporting by Ankur Banerjee in Bengaluru; Editing by Shinjini Ganguli)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up